Clinical Research in Southampton
Southampton Children's Hospital

A A A Text only | Accessibility | Privacy and cookies

Home
About the Trust
Our services
Patients and visitors
Our hospitals
Education
Research
Working here
Contact us

Browse site A to Z

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Search results

Go To Simple Search

Search Type: Criteria:

You could also try: distribute (102), allot (2)

Paclitaxel (7 day)

Description: Chemotherapy Protocol BLADDER CANCER PACLITAXEL (7 day) Regimen • Bladder Cancer – Paclitaxel (7 day) Indication • Treatment of locally advanced or metastatic bladder
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Paclitaxel-7-day.pdf

Vinflunine

Description: Chemotherapy Protocol BLADDER Regimen VINFLUNINE • Bladder – Vinflunine Indication • Bladder cancer that has failed to respond or progressed with in twelve months
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Bladdercancer/Vinflunine.pdf

Lenalidomide Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA LENALIDOMIDE There are multiple versions of this protocol in use. Please ensure you have the correct protocol for
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Lenalidomide-Ver-1.1.pdf

FC PO (5 day)-Cyclophosphamide-Fludarabine PO 5 day Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-FLUDARABINE ORAL 5 DAY (FC PO 5 day) Regimen Lymphoma – FC PO (5 day)-Cyclophosphamide-Fludarabine PO
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/FC-PO-5-day-Cyclophosphamide-Fludarabine-PO-5-day-Ver-1.1.pdf

Cyclophosphamide-Etoposide PO Ver 1.1

Description: Chemotherapy Protocol LYMPHOMA CYCLOPHOSPHAMIDE-ETOPOSIDE ORAL Regimen Lymphoma – Cyclophosphamide-Etoposide PO Indication Palliative treatment of malignant lymphoma Toxicity Drug Adverse Effect
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/Cyclophosphamide-Etoposide-PO-Ver-1.1.pdf

Paclitaxel (14day)

Description: Chemotherapy Protocol SARCOMA PACLITAXEL (14 day) Regimen • Sarcoma – Paclitaxel (14 day) Indication • Second line treatment of Kaposi sarcoma • WHO Performance status
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Sarcoma/Paclitaxel14day.pdf

Capecitabine 1250 (14)

Description: Chemotherapy Protocol BREAST CANCER CAPECITABINE 1250 (14 day) Regimen • Breast Cancer – Capecitabine 1250 (14 day) Indication • Treatment of locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine1250-14.pdf

Capecitabine 1000 (14)

Description: Chemotherapy Protocol BREAST CANCER CAPECITABINE 1000 (14 day) Regimen • Breast Cancer – Capecitabine 1000 (14 day) Indication • Treatment of locally advanced or
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Capecitabine1000-14.pdf

Vinorelbine Ver 1.1

Description: Chemotherapy Protocol BREAST CANCER VINORELBINE (INTRAVENOUS) Regimen Breast Cancer – Vinorelbine Indication Treatment of locally advanced or metastatic breast cancer that has
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Vinorelbine-Ver-1.1.pdf

Letrozole-Palbociclib

Description: Chemotherapy Protocol Breast Cancer Letrozole-Palbociclib Regimen • Breast Cancer – Letrozole-Palbociclib Indication • Palbociclib in combination with an aromatase inhibitor is indicated
Url: /Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Breastcancer/Letrozole-Palbociclib.pdf

111 to 120 of 181

Previous … 10 11 12 13 14 … Next